Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Iovance Biotherapeutics, Inc.’s reported figures.
Plus components not separately reported this period.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s EBIT?
- Iovance Biotherapeutics, Inc. (IOVA) reported EBIT of -$51.91M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s EBIT changed year-over-year?
- Iovance Biotherapeutics, Inc.'s EBIT increased by 54.4% year-over-year, from -$113.77M to -$51.91M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Iovance Biotherapeutics, Inc.'s EBIT has grown at a 4.2% compound annual growth rate (CAGR), from -$342.7M to -$403.36M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Iovance Biotherapeutics, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude